POSACONAZOLE — Competitive Intelligence Brief

POSACONAZOLE (POSACONAZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Azole Antifungal [EPC].

marketed Azole Antifungal [EPC] Small molecule

Target snapshot

POSACONAZOLE (POSACONAZOLE).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
POSACONAZOLE TARGET	POSACONAZOLE		marketed	Azole Antifungal [EPC]		2005-01-01
Vivjoa	OTESECONAZOLE	Mycovia Pharms	marketed	Azole Antifungal [EPC]	Cytochrome P450 3A4	2022-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Jublia	EFINACONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2014-01-01
Luzu	LULICONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2013-01-01
VORICONAZOLE	VORICONAZOLE		marketed	Azole Antifungal [EPC]		2002-01-01
Femstat 3	BUTOCONAZOLE	Bayer	marketed	Azole Antifungal		1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Azole Antifungal [EPC] class)

1. · 4 drugs in this class
2. Bausch Health · 2 drugs in this class
3. Bayer AG · 1 drug in this class
4. Johnson & Johnson (Janssen) · 1 drug in this class
5. Mycovia Pharms · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Pfizer Inc. · 1 drug in this class
8. Sebela Ireland Ltd · 1 drug in this class